Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial PerformanceBusiness Wire • 11/05/26
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - BuySeeking Alpha • 10/07/26
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Zacks Investment Research • 09/30/26
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 09/21/26
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare ConferenceBusiness Wire • 09/03/26
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View RaisedZacks Investment Research • 08/07/26
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter ResultsBusiness Wire • 08/06/26
Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum StockZacks Investment Research • 07/15/26
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting PatientsBusiness Wire • 07/14/26